The New York Academy of Sciences
Insights into the Resolution of Inflammation
Posted February 25, 2020
Inflammation is a common feature of many widely occurring human diseases. In recent years, our understanding of the molecular mechanisms regulating inflammation has improved dramatically, most notably with the identification of active processes that control the resolution of the inflammatory response. Now, this rapidly evolving field of research – Resolution Pharmacology — promises novel approaches for the treatment of myriad inflammatory diseases. In this webinar, the first in a four-part series, leaders in the field explore recent research on the molecular mechanisms driving the resolution of inflammation and approaches to therapeutically target these pathways in chronic inflammatory and autoimmune diseases.
In This Webinar, You’ll Learn
- The key steps required for the successful resolution of inflammation.
- How pro-resolving mediators, including lipoxins, resolvins, maresins, and protectins are biosynthesized and how they regulate resolution.
- How defects in resolution pathways contribute to chronic autoimmune and inflammatory conditions.
- Emerging strategies to therapeutically target the resolution of inflammation in diabetes and its associated complications including atherosclerosis, kidney disease, and fibrosis.
Charles Serhan, PhD, DSc
Harvard Medical School
Charles N. Serhan is a leading authority in inflammatory resolution and was first to identify the role of pro-resolving cellular mediators such as resolvins and lipoxins. He is the Simon Gelman Professor of Anesthesia at Harvard Medical School and Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine. He directs the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. Charles received his BS from Stony Brook University and his doctorate from NYU School of Medicine. He was a post-doctoral fellow at the Karolinska Institutet, Stockholm and joined the faculty at Harvard Medical School in 1987.
Catherine Godson, PhD, MRIA
University College Dublin
Catherine Godson studies the innate immune system and chronic complications of diabetes. Her research on inflammatory processes underlying diabetic complications has led to the identification of several novel therapeutic targets, susceptibility genes and potential modulators of disease. She is Full Professor of Molecular Medicine at University College Dublin (UCD), Director of the UCD Diabetes Complications Research Centre, and visiting Professor at Monash University, Melbourne. She was elected a member of the Royal Irish Academy in 2011 and received the Woman in Science Award of The International Congress of Inflammation, Sydney in 2019, in recognition of "outstanding research and leadership contributions."